Mamatha Bhat

Has grant

University Health Network
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Optimizing the Long-Term Health of Liver Transplant Recipients using Machine Learning Algorithms

Open Date: 2020-10-01

Close Date: 2022-10-01

Grant: Close

Use of Microbiome-Modifying Medications on Post-Transplant Metabolic Disease

Open Date: 2020-09-01

Close Date: 2021-05-01

Grant: Close

Image-guided Delivery of Lipoprotein-Like Nanoparticles to Safely Treat Hepatocellular Carcinoma

Open Date: 2020-09-01

Close Date: 2022-09-01

Grant: Close

Feasibility of a Home-Based Exercise Program in Lung Transplant Recipients to Improve Metabolic Syndrome

Open Date: 2020-07-01

Close Date: 2021-06-01

Grant: Close

Personalized Prevention of Hepatocellular Carcinoma

Open Date: 2020-06-01

Close Date: 2021-01-01

Articles (11)

Background: Liver transplantation (LT) is frequently lifesaving for people living with primary sclerosing cholangitis (PSC). However, patients are waitlisted for LT according to the model for end-stage liver disease-sodium (MELD-Na) score, which may not accurately reflect the burden of living with PSC. We sought to describe and analyze the clinical trajectory for patients with PSC referred for LT, in a mixed deceased donor/living donor transplant program. Methods: This was a retrospective cohort study from November 2012 to December 2019, including all patients with PSC referred for assessment at the University Health Network Liver Transplant Clinic. Patients who required multiorgan transplant or retransplantation were excluded. Liver symptoms, hepatobiliary malignancy, MELD-Na progression, and death were abstracted from chart review. Competing risk analysis was used for timing of LT, transplant type, and death. Results: Of 172 PSC patients assessed, 84% (n = 144) were listed of whom 74% were transplanted. Mean age was 47.6 years, and 66% were male. Overall mortality was 18.2% at 2 years. During the follow-up, 16% (n = 23) were removed from the waitlist for infection, clinical deterioration, liver-related mortality or new cancer; 3 had clinical improvement. At listing, 82% (n = 118) had a potential living donor (pLD). Patients with pLD had significantly lower waitlist and liver-related waitlist mortality (HR 0.20, p <0.001 and HR 0.17, p <0.001, respectively), and higher rates of transplantation (HR 1.83, p = 0.05). Exception points were granted to 13/172 (7.5%) patients. Conclusions: In a high-volume North American LT center, most patients with PSC assessed for transplant were listed and subsequently transplanted. However, this was a consequence of patients engaging in living donor transplantation. Our findings support the concern from patients with PSC that MELD-Na allocation does not adequately address their needs.

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021